BioMarin Pharmaceuticals BMRN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.5%-1.2pp | 77.7%-3.6pp | 81.3%+1.8pp | 79.6%+0.1pp | 79.4%-0.2pp | |
| Returns | ||||||
| Return on invested capital | 5.2%-1.4pp | 6.6%-2.1pp | 8.8%-1.9pp | 10.7%+2.2pp | 8.5%+0.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.8×+0.6× | 5.2×+0.4× | 4.8×-0.7× | 5.6×0.0× | 5.5×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Net debt / EBITDA | -3.8×-2.5× | -1.2×-0.3× | -0.9×-0.2× | -0.7×-0.1× | -0.6×+0.9× | |
| Per Share | ||||||
| Book value per share | $31.43+1.9% | $30.84-2.2% | $31.54+3.1% | $30.58+3.7% | $29.49+2.5% | |
| Valuation | ||||||
| Market capitalization | $10.86B-4.8% | $11.42B+9.8% | $10.4B-0.8% | $10.49B-22.2% | $13.49B+7.7% | |
| Price / sales | 3.4×-0.2× | 3.5×+0.2× | 3.4×-0.1× | 3.4×-1.1× | 4.6×+0.2× | |
| Price / book | 1.7×-0.1× | 1.9×+0.2× | 1.7×0.0× | 1.7×-0.6× | 2.3×+0.1× | |
| EV / EBITDA | 21.1×+1.1× | 20×+6.1× | 14×+2.5× | 11.5×-6.9× | 18.3×-1.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BioMarin Pharmaceuticals's profit margins?
- BioMarin Pharmaceuticals (BMRN) runs a 76.5% gross margin and a 19.9% operating margin, with a 16.8% net margin.
- Where do BioMarin Pharmaceuticals's ratios come from?
- Every ratio is computed from BioMarin Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
